Researchers working at with Seoul National University together with GPCR Therapeutics Inc. have focused on targeting pairs of G protein-coupled receptors (GPCRs) starting with the CXC chemokine ...

GPCR Therapeutics has secured target patents around prominent GPCRs such as CXCR4 and possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic ...

The agreement includes the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, along with technology transfer for the company's CXCR4 inhibitor, which is currently in Phase 2 clinical ...

GPCR Therapeutics, Inc. is developing a diverse pipeline targeting both CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers, and other GPCRs that promote or ...

Last September, GPCR published the paper on the direct interaction between two different GPCRs, CXCR4 and LPA1, in the peer-reviewed academic journal ‘Cell Communication and Signaling’ (1).

GPCR Therapeutics, Inc. is developing a diverse pipeline targeting both CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers, and other GPCRs that promote or ...